{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:56:58Z","timestamp":1760317018813,"version":"build-2065373602"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,7,27]],"date-time":"2004-07-27T00:00:00Z","timestamp":1090886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Drug resistance and early disease recurrence were major contributing factors in the limited survival of patients with acute lymphocytic leukemia (ALL). New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The current study evaluated the efficacy of a regimen comprising intravenous bolus injections of idarubicin, 12 mg\/m<jats:sup>2<\/jats:sup> daily \u00d7 3, and a continuous 7\u2010day infusion of cytosine arabinoside (ara\u2010C), 100 mg\/m<jats:sup>2<\/jats:sup> daily, in adults with refractory or recurrent ALL. Twenty patients aged 14\u201375 years were treated.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Six patients (30%) achieved complete remission (CR), 5 (25%) had a partial response (PR), and 9 (45%) did not respond. Recovery of blood counts occurred at a median of 20 days. One patient who achieved CR and one who achieved PR survived 1.5 and 2 years, respectively, after receiving this treatment. The median response and overall survival periods were 2.75 and 6.3 months, respectively. There was no relation between remission duration and previous chemotherapy. Neither leukocyte count at study entry nor patient karyotype was associated with attainment of CR. All patients experienced profound myelosuppression. Gastrointestinal toxicity was mild to moderate, with the exception of one case of World Health Organization Grade 3 mucositis.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The regimen of idarubicin and ara\u2010C achieved a 55% overall response rate in patients with recurrent or refractory ALL. This response rate compared favorably with other regimens and was achieved with acceptable toxicity. Response duration was disappointing, however. Cancer 2004. \u00a9 2004 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.20494","type":"journal-article","created":{"date-parts":[[2004,7,27]],"date-time":"2004-07-27T19:02:22Z","timestamp":1090954942000},"page":"1414-1419","source":"Crossref","is-referenced-by-count":9,"title":["Idarubicin and standard\u2010dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia"],"prefix":"10.1002","volume":"101","author":[{"given":"Merat","family":"Karbasian\u2010Esfahani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter H.","family":"Wiernik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yelena","family":"Novik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Paietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice P.","family":"Dutcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,7,27]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"804","article-title":"A phase I study of idarubicin dose escalation with amisfostine and high\u2010dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes","volume":"87","author":"Garicia\u2010Manero G","year":"2002","journal-title":"Haematologica."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a057675"},{"key":"e_1_2_6_4_2","first-page":"664","article-title":"A single high dose of idarubicin combined with high dose ARAC (MSKCC ALL\u20103 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University \u201cLa Sapienza\u201d of Rome","volume":"82","author":"Testi AM","year":"1997","journal-title":"Haematologica."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051624"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.6.789"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840715)54:2<207::AID-CNCR2820540205>3.0.CO;2-0"},{"key":"e_1_2_6_8_2","first-page":"869","article-title":"Doxorubicin and ifosfamide combination chemotherapy in previously treated acute leukemia in adults: a Southwest Oncology Group pilot study","volume":"64","author":"Ryan DH","year":"1980","journal-title":"Cancer Treat Rep."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.2.361.361"},{"key":"e_1_2_6_10_2","first-page":"856","article-title":"A phase I trial of a single high dose of idarubicin combined with high\u2010dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia","volume":"12","author":"Weiss MA","year":"1988","journal-title":"Leukemia."},{"issue":"4","key":"e_1_2_6_11_2","first-page":"S28","article-title":"Treatment of adult patients with relapsed or refractory acute lymphblastic leukemia","volume":"11","author":"Weiss MA","year":"1997","journal-title":"Leukemia."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1989.tb00304.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199701000-00010"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.5.813"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390904"},{"key":"e_1_2_6_16_2","first-page":"273","volume-title":"Neoplastic diseases of the blood","author":"Hoelzer D","year":"2003"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401803"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.2.313.313"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.8.1666.1666"},{"key":"e_1_2_6_20_2","first-page":"152","article-title":"Idarubicin: an anthracycline antineoplastic agent","volume":"11","author":"Cerososimo RJ","year":"1992","journal-title":"Clin Pharm."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-9671"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.1089"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770000193"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402046"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109064591"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.023"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0546-z"},{"key":"e_1_2_6_28_2","first-page":"34","article-title":"4\u2010Demethoxydaunorubicin (idarubicin) in relapsed and refractory acute myeloid leukemia","volume":"30","author":"Fulle HH","year":"1987","journal-title":"Haematol Blood Transfus."},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.1188"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10707"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04343.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709058605"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050258"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2053.x"},{"key":"e_1_2_6_35_2","first-page":"194","volume-title":"Neoplastic diseases of the blood","author":"Paietta E","year":"2003"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20494","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:15:31Z","timestamp":1760300131000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,27]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,9,15]]}},"alternative-id":["10.1002\/cncr.20494"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20494","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2004,7,27]]}}}